The anticoagulant effect of prolame, N-(3-hydroxy-1,3,5(10) estratrien-17ß-yl)-3-hydroxypropylamine, a novel amino-estrogen
Por:
Rubio-Póo C., Mandoki J.J., Mendoza-Patiño N., Lemini C., de la Peña A., Cruz F., Zavala E., Silva G., Garcia-Mondragón J., Fernández-G J.M., Soriano-Garcia M., Toscano A.R.
Publicada:
1 ene 1985
Resumen:
The anticoagulant and estrogenic effects of prolame, N- (3-hydroxy-1,3,5(10)-estratrien-17?-yl) -3-hydroxypropylamine, are described. A single subcutaneous injection of prolame in male mice, ovariectomized mice, adult and infant male rats, produced dose-dependent increases of blood clotting time, which could be observed with the larger doses even af-ter 4 days. In ovariectomized mice, prolame produced vaginal cornifications of shorter duration than those produced by estradiol-17?. The evidence suggests that, in contrast with currently used estrogens, prolame would not generate cardiovascular accidents if used for the treatment of prostatic carcinoma; it could also exceptionally effective for the prevention of thrombosis. © 1984.
Filiaciones:
Departamento de Farmacología, Facultad de Medicina, Mexico
Instituto de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Mexico, D.F. C.P. 04510, Mexico
|